Palvella Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
29
- Stock Symbol
-
PVLA
- Investments
-
1
- Share Price
-
$152.48
- (As of Friday Closing)
Palvella Therapeutics General Information
Description
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Contact Information
Website
www.palvellatx.comCorporate Office
- 353 West Lancaster Avenue
- Suite 200
- Wayne, PA 19087
- United States
Corporate Office
- 353 West Lancaster Avenue
- Suite 200
- Wayne, PA 19087
- United States
Palvella Therapeutics Timeline
Palvella Therapeutics Stock Performance
As of 13-Nov-2026, Palvella Therapeutics’s stock price is $152.48. Its current market cap is $2.23B with 14.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $152.48 | $153.18 | $72.22 - $179.95 | $2.23B | 14.6M | 238K | -$5.53 |
Palvella Therapeutics Financials Summary
As of 30-Sep-2026, Palvella Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,737,303 | 1,179,496 | 200,083 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (72,203) | (38,487) | (13,759) | 12,426 |
| Net Income | (74,994) | (41,715) | (17,434) | 18,691 |
| Total Assets | 239,402 | 59,559 | 88,234 | 7,548 |
| Total Debt | 485 | 633 | 0 | 0 |
Palvella Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Palvella Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Palvella Therapeutics Comparisons
Industry
Financing
Details
Palvella Therapeutics Competitors (49)
One of Palvella Therapeutics’s 49 competitors is Mabworks Biotech, a Venture Capital-Backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mabworks Biotech | Venture Capital-Backed | Beijing, China | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Cogent Biosciences | Formerly VC-backed | Waltham, MA | ||||
| Innovimmune Biotherapeutics | Accelerator/Incubator Backed | New York, NY | ||||
| Seagen | Formerly VC-backed | Bothell, WA |
Palvella Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Palvella Therapeutics Patents
Palvella Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4401730-A1 | Compositions of rapamycin and their use in the treatment of microcystic lymphatic malformation | Pending | 15-Sep-2021 | ||
| EP-4401730-A4 | Compositions of rapamycin and their use in the treatment of microcystic lymphatic malformation | Pending | 15-Sep-2021 | ||
| US-20250228825-A1 | Compositions of rapamycin and their use in the treatment of microcystic lymphatic malformation | Pending | 15-Sep-2021 | ||
| WO-2023043900-A1 | Compositions of rapamycin and their use in the treatment of microcystic lymphatic malformation | Inactive | 15-Sep-2021 | ||
| US-20230113775-A1 | Anhydrous compositions of egfr inhibitors and methods of use | Inactive | 10-Sep-2021 | A61K31/517 |
Palvella Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Palvella Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Palvella Therapeutics Acquisitions (1)
Palvella Therapeutics’s most recent deal was a Merger/Acquisition with Pieris Pharmaceuticals. The deal was made on 13-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pieris Pharmaceuticals | 13-Dec-2024 | Merger/Acquisition | Drug Discovery |
Palvella Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Palvella Therapeutics FAQs
-
When was Palvella Therapeutics founded?
Palvella Therapeutics was founded in 2015.
-
Where is Palvella Therapeutics headquartered?
Palvella Therapeutics is headquartered in Wayne, PA.
-
What is the size of Palvella Therapeutics?
Palvella Therapeutics has 29 total employees.
-
What industry is Palvella Therapeutics in?
Palvella Therapeutics’s primary industry is Drug Discovery.
-
Is Palvella Therapeutics a private or public company?
Palvella Therapeutics is a Public company.
-
What is Palvella Therapeutics’s stock symbol?
The ticker symbol for Palvella Therapeutics is PVLA.
-
What is the current stock price of Palvella Therapeutics?
As of 13-Nov-2026 the stock price of Palvella Therapeutics is $152.48.
-
What is the current market cap of Palvella Therapeutics?
The current market capitalization of Palvella Therapeutics is $2.23B.
-
Who are Palvella Therapeutics’s competitors?
Mabworks Biotech, CytomX Therapeutics, Cogent Biosciences, Innovimmune Biotherapeutics, and Seagen are some of the 49 competitors of Palvella Therapeutics.
-
What is Palvella Therapeutics’s annual earnings per share (EPS)?
Palvella Therapeutics’s EPS for 12 months was -$5.53.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
